Insider Selling: Prestige Consumer Healthcare (NYSE:PBH) VP Sells $43,140.00 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the sale, the vice president owned 42,329 shares of the company’s stock, valued at $2,539,740. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Jeffrey Zerillo also recently made the following trade(s):

• On Monday, December 1st, Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $60.00, for a total value of $16,860.00.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $59.99 on Friday. The business has a 50-day simple moving average of $61.05 and a two-hundred day simple moving average of $70.07. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of 14.88, a PEG ratio of 1.89 and a beta of 0.39. Prestige Consumer Healthcare Inc. has a 52 week low of $57.25 and a 52 week high of $90.04. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The business had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. During the same quarter in the previous year, the firm earned $1.09 earnings per share. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBH. UMB Bank n.a. grew its stake in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after acquiring an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the period. Maseco LLP bought a new position in Prestige Consumer Healthcare in the second quarter worth approximately $27,000. First Horizon Corp purchased a new position in Prestige Consumer Healthcare during the 3rd quarter worth $32,000. Finally, Barrow Hanley Mewhinney & Strauss LLC raised its position in Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PBH shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a research note on Wednesday, September 24th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Oppenheimer reduced their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.